文献速递眼底病与葡萄膜炎

阿柏西普优先用于新生血管性年龄相关性黄斑变性的「治疗并延长」玻璃体内治疗两年结局

TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2018-01-01

这项数据库观察性研究纳入136只眼(123例患者),在「治疗并延长」方案下接受阿柏西普单药治疗24个月。平均视力从基线61.4个字母提升至24个月67.4个字母(+6.0个字母,95%CI 3.3-8.5,P<0.001),第二年注射次数和就诊次数较第一年减少。

要点

  • 24个月平均视力提升+6.0个字母(95%CI 3.3-8.5,P<0.001)。
  • 视力≥70个字母(20/40)的眼比例从40%增至58%(P<0.001)。
  • 第二年注射次数(5.7 vs 7.8)和就诊次数(6.5 vs 8.7)较第一年减少(均P<0.001)。

核心结论

  • 在常规临床实践中以「治疗并延长」方案使用阿柏西普单药治疗,可获得良好视力结局,同时减少治疗和就诊负担。

研究设计与样本

  • 数据库观察性研究,纳入2012年11月1日至2014年1月31日期间在「Fight Retinal Blindness!」结局登记系统中追踪、完成24个月阿柏西普单药「治疗并延长」方案治疗的初治新生血管性年龄相关性黄斑变性眼。
  • 研究人群为136只眼(来自123例患者),平均(SD)年龄77.2(7.0)岁,59%为女性。

主要发现

  • 平均视力从基线61.4个字母(约20/60;SD 17.4)提升至24个月67.4个字母(约20/45;SD 17.7),变化+6.0个字母(95%CI 3.3-8.5;P<0.001)。
  • 从基线至24个月,视力≥70个字母(20/40)的眼比例从40%增至58%(P<0.001),视力≤35个字母(20/200)的眼比例保持10%不变(P=0.547)。
  • 基线视力≥70个字母(20/40)的眼中,98%在24个月时仍能维持该视力。
  • 完成24个月治疗的眼,第二年较第一年平均注射次数减少(5.7[2.6] vs 7.8[2.1];P<0.001),平均就诊次数减少(6.5[2.4] vs 8.7[1.7];P<0.001)。
  • 将60只未完成2年随访的合格眼及14只换用雷珠单抗的眼以末次观测值结转法纳入后,视力较基线平均变化+5.6个字母(95%CI 3.3-7.7)。

临床怎么用

  • 原文结论指出,在常规临床实践中以「治疗并延长」方案使用阿柏西普单药治疗,可获得良好视力结局,同时减少治疗和就诊负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 24-month outcomes of a treat and extend (T&E) regimen using aflibercept in eyes with neovascular age-related macular degeneration. METHODS: This was a database observational study that included treatment-naive eyes with neovascular age-related macular degeneration tracked by the Fight Retinal Blindness! outcome registry completing 24 months of sole monotherapy with aflibercept treatment under a T&E regimen between November 1, 2012 and January 31, 2014. Locally weighted scatterplot smoothing curves were used to display visual acuity outcomes. Main outcome measures were change in visual acuity at 24 months and number of injections and visits during the study period. RESULTS: The study population, identified by reviewing the database, consisted of 136 eyes from 123 patients completing 24 months of follow-up on aflibercept. Mean (SD) age was 77.2 (7.0) years, 59% were female. Mean visual acuity increased from 61.4 (∼20/60; SD 17.4) letters at baseline to 67.4 (∼20/45; SD 17.7) letters at 24 months (+6.0 letters [95% confidence interval: 3.3-8.5]; P < 0.001). From baseline to 24 months, the proportion of eyes with visual acuity ≥70 letters (20/40) increased (40%-58%, P < 0.001) and the proportion of eyes with visual acuity ≤35 letters (20/200) remained the same (10%; P = 0.547). Ninety-eight per cent of eyes starting with visual acuity ≥70 letters (20/40) were able to maintain this up to 24 months. From the first to the second year of treatment, the mean number of injections (7.8 [2.1] vs. 5.7 [2.6]; P < 0.001) and visits (8.7 [1.7] vs. 6.5 [2.4]; P < 0.001) decreased for eyes completing 24 months of treatment. When data from 60 eligible eyes that did not complete 2 years follow-up, along with 14 eyes that switched to ranibizumab, were included using last observation carried forward, the mean change in visual acuity from baseline was +5.6 letters (95% confidence interval: 3.3-7.7). CONCLUSION: These data indicate that eyes treated with aflibercept, as a sole therapy, in routine clinical practice with a T&E regimen can achieve good visual outcomes while decreasing the burden of treatments and clinic visits.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Barthelmes D, Nguyen V, Daien V, et al. TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2018. PMID: 28145976. doi:10.1097/IAE.0000000000001496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。